Another Gene Therapy Developer Partners Up, This Time with Genzyme
Insights - Genzyme (of Sanofi [SNY]) announced on Wednesday a collaboration with the private gene therapy company Voyager Therapeutics.
Read NowInsights
Pfizer to Strengthen Established Products Business with Hospira Acquisition
Insights - Pfizer (PFE) announced plans to buy injectable generics & biosimialar developer Hospira (HSP) at $90/share, for an enterprise value of $17 billion. Hospira closed Wednesday at $64.80.
Read Now
For the First Time, the FDA Takes Back a Breakthrough Therapy Designation
Insights - Merck (MRK) revealed on Wednesday that the U.S. FDA has rescinded a Breakthrough Therapy Designation for its investigational Hepatitis C treatment.
Read Now
Your 30-Second Primer on this Week’s Hottest IPO, Spark Therapeutics
Insights - Spark Therapeutics (ONCE) lists publicly today, joining companies like bluebird bio (BLUE) and Avalanche (AAVL) as yet another emerging gene therapy player.
Read Now
Intercept Gains a Cool Billion in After Hours Trading
Insights - Intercept Pharmaceuticals (ICPT) added over $1 billion to its value in late trading when its lead drug received a Breakthrough Therapy Designation
Read Now
Wall Street is Behind the Curve on Foreign Exchange Impact
Insights - Across the market, multinational companies are blaming missed earnings and lower-than-expected 2015 guidance on foreign exchange effects and cheap oil.
Read Now
Regeneron’s New Cholesterol Drug is a Month Ahead of Amgen’s: Is that Worth $70 Million?
Insights - That's what Regeneron (REGN) and Sanofi (SNY) paid for a FDA Priority Review Voucher that will shorten the review time for the PCSK9 inhibitor, alirocumab.
Read Now